OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also evaluating OK-101 to treat NCP patients with the just announced opening of a Phase 2 trial to treat the debilitating conditions of NCP.

OKYO Pharma (OKYO) is a client of RedChip Companies, Inc. OKYO agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in August 2024, and 50,000 stock options with a $1 strike price and five-year expiration, for six month of investor awareness services. RedChip intends to and will, if possible, exercise and sell all of its options immediately upon eligibility, and you may be buying as RedChip is selling. OKYO also agreed to pay RedChip a one-time forty-four thousand dollar fee for a 10-day national TV ad campaign aired June 11 through June 25, 2024, a one-time twenty-thousand dollar fee for a five-day national TV ad campaign aired August 5 through August 9, 2024, a one-time thirty-eight-thousand five-hundred dollar fee for a 10-day national TV ad campaign aired October 16 through October 29, 2024, and a one-time #33,000 cash fee for a 10-day national TV ad campaign aired November 7 through November 20, 2024.

Read our full disclosures at: www.redchip.com/legal/disclosures